Predict your next investment

Private Equity
logoscapital.com

See what CB Insights has to offer

Investments

69

Portfolio Exits

37

Funds

2

About Logos Capital

Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.

Logos Capital Headquarter Location

345 California St Suite 600

San Francisco, California, 94104,

United States

415-747-7342

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Logos Capital News

Cedilla Therapeutics Completes $82.6M Series B Financing

Oct 26, 2021

Cedilla Therapeutics Completes $82.6M Series B Financing -- Additional $25 million in funding and expansion of syndicate with leading healthcare funds, RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital – -- Jake Simson, Ph.D., Partner at RA Capital Management, joins Cedilla Board of Directors -- CAMBRIDGE, Mass., October 25, 2021-- Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 million. The oversubscribed Series B expansion includes new investors RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital, along with participation from existing investor Third Rock Ventures. “We are grateful for the support from our new and existing investors, which reflects the promise of our novel approach to conditionally modulating proteins as well as the unique potential of our lead programs, inhibitors against TEAD and CDK2, two critical but historically undruggable targets,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “With this financing, we plan to accelerate and expand our development efforts by progressing our most advanced programs toward the clinic while continuing to invest in ongoing discovery efforts against additional high value cancer targets.” Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach and esophageal cancers. The company plans to initiate investigational new drug application-enabling studies for the TEAD program in the first half of 2022 and for the CDK2 program in the second half of 2022. In conjunction with the financing, Jake Simson, Ph.D., Partner at RA Capital Management, joins Cedilla’s Board of Directors. Dr. Glucksmann continued, “We are pleased to welcome Jake to our Board of Directors. He brings a wealth of experience advising companies from the earliest stages of company formation through their maturation into fully integrated biopharmaceutical organizations. We look forward to his many contributions as we continue to grow Cedilla into a clinical-stage organization with a robust and growing portfolio of product candidates.” “Cedilla brings a new dimension to precision oncology by conditionally modulating proteins in their functional state,” said Jake Simson, Ph.D., Partner at RA Capital Management. “Preclinical data generated to-date suggest that Cedilla’s lead programs may challenge historical perceptions of TEAD and CDK2 as undruggable targets and could offer patients new options that would be well-tolerated and extremely effective. In addition, Cedilla’s approach, based on a deep understanding of how the cellular context modulates protein activity, could deliver superior inhibitors against a range of other key cancer drivers. I look forward to partnering with the team with the aim to deliver a broad portfolio of small molecule medicines, each with potential profound benefit to patients.” About Cedilla Therapeutics Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. Follow our journey at www.cedillatx.com and LinkedIn. Contact:

Logos Capital Investments

69 Investments

Logos Capital has made 69 investments. Their latest investment was in Arbor Biotechnologies as part of their Series B on November 11, 2021.

CBI Logo

Logos Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/9/2021

Series B

Arbor Biotechnologies

$215M

Yes

4

10/26/2021

Series C

Quanta Therapeutics

$60M

Yes

3

10/25/2021

Series B - II

Cedilla Therapeutics

$25M

Yes

2

9/29/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

9/20/2021

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/9/2021

10/26/2021

10/25/2021

9/29/2021

9/20/2021

Round

Series B

Series C

Series B - II

Series B

Series A - III

Company

Arbor Biotechnologies

Quanta Therapeutics

Cedilla Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$215M

$60M

$25M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

3

2

10

10

Logos Capital Portfolio Exits

37 Portfolio Exits

Logos Capital has 37 portfolio exits. Their latest portfolio exit was LianBio on November 01, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/1/2021

IPO

2

10/21/2021

IPO

$991

15

10/8/2021

IPO

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

11/1/2021

10/21/2021

10/8/2021

00/00/0000

00/00/0000

Exit

IPO

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

15

2

10

10

Logos Capital Fund History

2 Fund Histories

Logos Capital has 2 funds, including Logos Opportunities Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/10/2019

Logos Opportunities Fund I

Late-Stage Venture Capital

$6M

1

Logos Opportunities Fund II

Subscribe to see more

$99M

10

Closing Date

9/10/2019

Fund

Logos Opportunities Fund I

Logos Opportunities Fund II

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Status

Amount

$6M

$99M

Sources

1

10

Logos Capital Team

3 Team Members

Logos Capital has 3 team members, including current Managing Partner, Arsani William.

Name

Work History

Title

Status

Graham Walmsley

Founder

Current

Graham Walmsley

Founder

Current

Arsani William

Managing Partner

Current

Name

Graham Walmsley

Graham Walmsley

Arsani William

Work History

Title

Founder

Founder

Managing Partner

Status

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.